[13C,15N2]-Cytarabine

[13C,15N2]-Cytarabine is a stable isotope-labeled version of cytarabine, a chemotherapy drug used to treat various types of cancer, including leukemia, lymphoma, and solid tumors. It works by inhibiting DNA synthesis, thereby preventing cancer cells from growing and dividing. [13C,15N2]-Cytarabine is used for research and diagnostic purposes, particularly in the development of new cancer treatments and the study of cellular metabolism. The stable isotope labeling of [13C,15N2]-Cytarabine provides a unique tool for studying the pharmacokinetics and metabolic fate of cytarabine in vivo. This is because the stable isotopes incorporated into the drug molecule do not undergo radioactive decay and can be traced using mass spectrometry. This allows researchers to determine the drug's distribution, elimination, and metabolism in the body, as well as its effects on cancer cells. Chemically, [13C,15N2]-Cytarabine is a nucleoside analog, meaning it mimics the structure of a nucleotide, the building block of DNA. It contains two stable isotopes, carbon-13 and nitrogen-15, which replace the naturally occurring carbon and nitrogen atoms in the molecule. These isotopes do not significantly alter the drug's pharmacological properties but allow for precise measurement and tracking of the drug's behavior in biological systems. Overall, [13C,15N2]-Cytarabine is a valuable tool for cancer research and drug development, providing insights into the mechanism of action and pharmacokinetics of cytarabine and facilitating the development of new and more effective cancer treatments.